ASCO 2021 | The future of NSCLC treatment
Benjamin Besse, MD, PhD, Gustave Roussy Cancer Institute, Paris, describes new treatments and targets currently under investigation. Prof. Besse discusses the toxicity and progression-free survival (PFS) rate of sotorasib in first-line treatment as well as DZD9008, an EGFR inhibitor assessed in patients with advanced non-small-cell lung cancer (NSCLC). Additional treatments discussed include patritumab deruxtecan, a novel HER3-directed antibody-drug conjugate (ADC), which has shown promise in patients with EGFR-mutated NSCLC. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Benjamin Besse, MD, PhD has received sponsored research funds from 4D Pharma, Abbvie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Inivata, Janssen, Onxeo, OSE immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals.
